Potential Restoration of the Infant Microbiome

NCT ID: NCT02407184

Last Updated: 2018-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Understanding the microbiome's important role in human health, the investigators wish to determine how the development of the infant microbiome is impacted by delivery mode, comparing natural vaginal birth to scheduled C-sections. Investigators will look at the oral, nasal, skin, vaginal and fecal bacteria of 78 mothers and their infants from birth to age 1.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Human microbiota play an important role in the functioning of various organs, as well as the education of the immune system. Mammals have evolved to be born non-sterile, covered with the maternal vaginal bacteria that populate the maternal birth canal, as well as to exclusively breastfeed during early development. Unfortunately, these processes are substantially altered with modern Western practices, which may have health consequences. In particular, C-section is associated with an increased risk of immune diseases and allergies. This study explores the effects of exposing neonates to the vaginal environment at birth, perinatal antibiotics, and lactation on the acquisition of new microbial genes during the first year of infant microbiome development.

This study follows 78 babies from healthy mothers (18-40 years old) with uncomplicated pregnancies. The babies are divided into three groups according to their exposure to the vaginal environment at birth:

Group 1: (n-26) Babies born via vaginal delivery.

Group 2: (n-26) Babies born via scheduled C-section without exposure to mother's vaginal bacteria just after birth.

Group 3: (n-26) Babies born via scheduled C-section with exposure to mother's vaginal microbiota just after birth.

Sampling Time Points:

Subjects may join the study at any point during their pregnancy or soon after delivery. If possible, samples of the mother will be obtained three times prior to delivery in the third trimester: at 30, and 4 or fewer days prior to the mother's due date, as well as on the day of birth prior to delivery. If not possible, samples of mothers and babies can be obtained from birth onwards. Samples will be collected from both mother and baby at day 1, day 2 or 3, weekly through the first month, and monthly through the first year. During monthly sampling, a member of the study team will communicate with mothers regularly to assess for any changes in the infant's diet or health between visits.

Body Sites to be Sampled on Mother and Baby:

At each sampling, a total of 6 samples will be taken from the baby (feces, mouth, nose, forehead skin, right forearm skin, right hand skin) and 9 will be taken from the mother (same as for the babies plus right areola, vagina, and breast milk). Sampling will consist of simple swabbing of the designated body sites, as well as the collection of mother's breast milk.

Each time samples are collected, information about the subject's diet, medication and supplement use, sleep, physical activity and overall health will be asked by survey in order to correlate changes in the life of the subject with changes in his/her microbiota.

C-section with Exposure to the Vaginal Environment Procedure:

Mothers who give birth at NYULMC or Bellevue Hospital and comply with the inclusion and exclusion criteria for exposure to maternal vaginal contents can choose to expose their newborn to samples of their vaginal microbiome just after birth. Such mothers will be tested to confirm that their vaginal pH is acidic (pH ≤ 4), which indicates the dominance of lactic acid bacteria. Testing of vaginal pH will be performed using pH paper. These procedures require of the presence of a study member and will only be performed at NYULMC or Bellevue hospitals.

Samples of vaginal bacteria will be collected prior to C-section. A piece of gauze will be placed in the birth canal just after antibiotic administration, and removed just before the caesarian procedure begins. This period will be no longer than 1 hour long. However, any amount of time the gauze is in the birth canal will be sufficient to proceed with the swabbing procedure. Once removed from the mother, the gauze will be stored in a sterile container until birth. Immediately after delivery, a trained study team member will swab the neonate with the gauze at multiple body sites, starting with the mouth, the face, and then subsequently the remainder of his/her body. After the swabbing, the 6 samples normally taken from all newborns will be collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Microbiome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Scheduled C-section

Babies that are scheduled to be born in a hospital via standard C-section procedure.

Group Type NO_INTERVENTION

No interventions assigned to this group

Vaginal Delivery

Babies that are born via vaginal delivery, either at home, at a birthing center or hospital. Drugs may be administered during labor.

Group Type NO_INTERVENTION

No interventions assigned to this group

Scheduled C-section with Exposure

Babies that are scheduled to be born in a hospital via standard C-section procedure, as well as are swabbed with gauze containing their mother's vaginal microbiota just after delivery. The intervention: Newborn exposure to mother vaginal microbiota.

Group Type EXPERIMENTAL

Newborn exposure to mother vaginal microbiota

Intervention Type OTHER

Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Newborn exposure to mother vaginal microbiota

Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy mothers, 18-40 years old with uncomplicated pregnancies delivering at term (37 weeks or later)
* Mothers of any ethnic or social background that can speak, read, and understand English to the extent that they can consent in English OR mothers who do not speak English yet agree to come to an NYU hospital for all sampling.


* Scheduled C-section
* Vaginal pH ≤ 4 at the time of birth (as measured via pH paper)

Exclusion Criteria

* Mothers with pre-eclampsia or other serious chronic conditions
* Mothers with complicated pregnancies
* Mothers under 18 years of age or over 40 years of age
* Babies with complications during delivery
* Babies delivered prior to 37 weeks of gestation


* Mothers reported positive to active primary herpes, genital warts, HIV, Group B Streptococcus, gonorrhea, chlamydia, bacterial vaginosis, yeast infection, or trichomoniasis.
* Mothers with vaginal pH \> 4 at the time of birth (as measured via pH paper).
* Known positive Group B Strep test results by rectal vaginal swab within five weeks of the scheduled caesarian.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NYU Langone Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maria Gloria Dominguez-Bello, PhD

Role: PRINCIPAL_INVESTIGATOR

NYU School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

14-01446

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Maternal- Fetal Infection
NCT03371056 UNKNOWN NA